Sensus Healthcare, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US81728J1097
USD
4.02
-0.04 (-0.99%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Sensus Healthcare, Inc. stock-summary
stock-summary
Sensus Healthcare, Inc.
Pharmaceuticals & Biotechnology
Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. It uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100 Plus and SRT-100 Vision. The Company's product, the SRT-100, is a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions, such as keloids. The SRT-100 treats primary lesions in the sensitive areas of the head and neck region. Its Sensus Laser Aesthetic Solutions division provides a range of in-office aesthetic dermatology procedures including facial rejuvenation, wrinkle removal, body sculpting/fat removal as well as other aesthetic applications.
Company Coordinates stock-summary
Company Details
851 Broken Sound Pkwy NW Ste 215 , BOCA RATON FL : 33487-3635
stock-summary
Tel: 1 561 92258081 212 8383777
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 12 Schemes (10.19%)

Foreign Institutions

Held by 17 Foreign Institutions (2.51%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Joseph Sardano
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Ms. Megan Cornish
Director
Mr. Anthony Petrelli
Non-Employee Director
Dr. John Heinrich
Non-Executive Independent Director
Mr. William McCall
Non-Executive Independent Director
Mr. Samuel O'Rear
Non-Executive Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
7 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 53 Million (Micro Cap)

stock-summary
P/E

45.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.42

stock-summary
Return on Equity

-1.63%

stock-summary
Price to Book

1.02